Celina Whalley M.Sc.


Celina Whalley, MSc

Celina Whalley is a scientific writer with expertise in genomics, residing in West Midlands, UK.

20+ years of experience working with University Genomic Service laboratories specializing in:

  • RNA, DNA and cfDNA extraction, along with QC, from biological samples
  • Microarrays for methylation, genotyping, and gene expression
  • Next Generation Sequencing (NGS) library preparation with DNA and RNA
  • Operation of Illumina sequencing platforms
  • Oxford Nanopore long read library preparation with DNA and RNA
  • Operation of Oxford Nanopore MinION/GridION and PromethION platforms
  • 10x single cell mRNA-seq library preparation and NGS


  • BSc Biology, University of Lancaster, UK
  • MSc Medical Mycology, University of Leeds, UK


  • Registered Scientist (RSci)
  • Chartered Scientist (CSci)

Professional Memberships

GALEAS Hereditary Plus

New genetic test to speed up and streamline diagnosis of inherited cancers

By Paula | January 24, 2024

Genetic testing company, Nonacus, has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS Hereditary Plus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations.

Genetic testing for hereditary cancers: challenges and opportunities for genomic centres

By Victoria Simms | December 20, 2023

Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.

4 key factors influencing NGS custom panel design

By Tom Lendzion | December 8, 2023

Effective probe-set design ensures comprehensive target coverage and heightened sensitivity. A poor design can lead to missed opportunities in detecting critical genetic variants.

Photo of a DNA sample tube

FFPE, cfDNA and gDNA: The guide to DNA sample types used in next generation sequencing

By Tom Lendzion | December 8, 2023

Explore the transformative power of next-generation sequencing and the mysteries of DNA with our detailed guide on FFPE, cfDNA, and gDNA sample types.

Shot of two doctors shaking hands at a clinic

How our custom NGS panels are being used for clinical utility

By Tom Lendzion | November 29, 2023

Targeted Next Generation Sequencing (NGS) panels have revolutionized clinical diagnosis and treatment of genetic disorders and cancers by being able to precisely identify disease-associated variants.

SPRI technology magnetic beads

The power of SPRI technology: Tips for DNA size selection and effective cleanup in NGS workflows

By Tom Lendzion | November 1, 2023

Since its introduction into genomics in 1995, Solid Phase Reversible Immobilization (SPRI) technology, in the form of magnetic beads, has become mainstream in laboratory protocols for nucleic acid extraction and purification.

Nonacus CEO Chris Sale and Advanced Genomics APAC Managind Director Andy Chang

Grand Opening of Advanced Genomics APAC Taiwan Headquarters

By Tom Lendzion | October 5, 2023

Advanced Genomics APAC Co. Ltd. proudly announced today the grand opening of its Taiwan headquarters, marking a significant milestone in its mission to revolutionize medical diagnosis and advance the field of cancer genomics.

The NEW sample-to-report NGS bladder cancer test: GALEAS Bladder – All you need to know

By Victoria Simms | September 20, 2023

To improve bladder cancer management for both patients and clinicians, Nonacus developed and launched GALEAS Bladder. This urine-based molecular biomarker test is highly accurate and sensitive at detecting all stages and grades of bladder cancer. It provides a simple sample-to-report, molecular triage for patients with hematuria; streamlining the clinical diagnosis process and reducing the need for cystoscopies.

To consolidate multiple testing strategies for haematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia

By Victoria Simms | August 2, 2023

To help consolidate multiple testing strategies for haematological malignancies, our customer designed a Nonacus NGS panel, creating the first NGS workflow for both myeloid and lymphoid neoplasia.

Detecting copy number variants using Next Generation Sequencing

By Victoria Simms | June 30, 2023

Copy number variants are responsible for 5-10% of genetic disease – that’s why detecting them reliably and robustly is so important in clinical labs. Next Generation Sequencing panels have proven to be extremely useful for clinical applications and can successfully detect many genomic variants, but they can often struggle with CNV detection.